Fig. 3From: Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomasCorrelative analyses of MMP-2, MMP-9 and sIL-2Rα in the CSF. (a to d) Activated MMP-2 has a bias toward lower levels when compared to baseline during treatment with mTMZ. The mean MMP-2 level has a direct correlation with OS but not PFS. (e to h) The level of activated MMP-9 is highly variable during treatment with mTMZ, but there was no correlation with OS or PFS. (i to l) sIL-2Rα levels are also highly variable among individual patients. Baseline sIL-2Rα level has an inverse correlation with time from initial diagnosis to first recurrence. There is a trend for correlation between increased sIL-2Rα level and OS but not PFSBack to article page